This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Creative BioMart
product type :
antibody
product name :
Anti-KRT8 monoclonal antibody, clone D-54 [FITC]
catalog :
DCABH-6311
quantity :
50 μg
clonality :
monoclonal
host :
mouse
conjugate :
FITC
clone name :
D-54
reactivity :
human
application :
flow cytometry
product information
Cat :
DCABH-6311
Product Name :
Anti-KRT8 monoclonal antibody, clone D-54 [FITC]
Brand :
Creative Diagnostics
Abbr :
Anti-KRT8 MAb, FITC-Conjugated
Host animal :
Mouse
Clone :
D-54
Official Symbol :
KRT8
Clonality :
Monoclonal
Application :
FC
Target :
KRT8
Species Reactivity :
Human
Conjugate :
FITC
Antibody Type :
Primary Antibodies
Immunogen :
Tissue, cells or virus corresponding to Human Cytokeratin 8. Cytoskeleton preparation from HeLa Human cervix carcinoma cell line.Database link: P05787
Alternative Names :
KRT8; keratin 8; keratin, type II cytoskeletal 8; CARD2; CK8; CYK8; K2C8; K8; KO; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; CK-8;
UniProt ID :
Q7L4M3
Antibody Isotype :
IgG1
Size :
50 μg
Storage :
Store at +4°C. Do Not Freeze. Store In the Dark.
company information
Creative BioMart
Creative BioMart provides quality recombinant proteins, diagnostic antibodies and antigens, diagnostic enzymes and pharmaceutical enzymes to the research community of biology, clinical research, molecular diagnostics and biopharmaceutical drug development.
We are offering more than 3,000 recombinant proteins, peptides and antibodies. All the products are rigorously tested to meet the most demanding research needs. At the same time, lowest prices in the industry are always guaranteed.
Also, in order to leverage our core competencies and resources, Creative BioMart has formed a large number of corporate partnerships and academic collaborations for product development and distribution. We welcome potential partners and distributors to explore business relationships with Creative BioMart.
questions and comments